Octreotide Teva (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreotide Teva, is a peptide synthetic analog of somatostatin presented as a 100 µg/mL solution for subcutaneous injection use. It regulates hormone secretion and is employed in the management of certain endocrine‑related tumors and related complications.

GNH USA supplies Octreotide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Octreotide Teva is a somatostatin analogue that modulates neuroendocrine activity in several disease pathways.

- Acromegaly: reduces excessive growth hormone secretion and helps control serum IGF‑1 levels. - Neuroendocrine tumors (carcinoid syndrome): alleviates flushing and diarrhea by inhibiting vasoactive peptide release. - Preventing postoperative postoperative pancreatic fistula: decreases pancreatic secretions after major abdominal surgery. - Control of severe hypoglycaemia related to insulinoma or sulfonylurea overdose. - Management of refractory gastrointestinal bleeding associated with portal hypertension.

Octreotide may elicit a range of adverse reactions, most of which are dose‑dependent and reversible upon discontinuation.

Common Side Effects: - Nausea and vomiting - Abdominal pain or cramping - Diarrhea or loose stools - Injection site erythema or discomfort - Headache - Mild hyperglycaemia or hypoglycaemia

Serious or Rare Side Effects: - Gallbladder sludge or gallstones - Severe hyperglycaemia requiring insulin therapy - Acute pancreatitis - Cardiac arrhythmias - Anaphylactic or severe hypersensitivity reactions - Hepatic dysfunction with elevated transaminases

Octreotide should be used with careful clinical monitoring and appropriate patient education.

- Renal impairment: adjust monitoring frequency as drug clearance may be reduced. - Hepatic dysfunction: observe for altered metabolism and potential accumulation. - Diabetes mellitus: monitor blood glucose closely, as the drug can cause hyper‑ or hypoglycaemia. - Cardiac disease: watch for brady‑cardia or arrhythmias, especially in patients with pre‑existing conduction abnormalities. - Pregnancy: evaluate risk‑benefit ratio; use only if clearly needed. - Store at 2-8°C: keep refrigerated (do not freeze) and protect from light ; ensure the vial remains in its original pack.

Octreotide can interact with several concomitant medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Cyclic peptide c‑    ");

Moderate ");

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - \n